ArticlebioRxiv : the preprint server for biology2026
Tracing PFAS Transfer from Mother to the Fetoplacental Unit: Insights from Trimester-Specific Maternal Serum Profiles.
Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Per- and polyfluoroalkyl substances (PFAS) are ubiquitous endocrine-disrupting pollutants that cross the placenta and affect offspring health, but the extent and timing of their transfer to placental and fetal compartments remain poorly understood. We characterized the relationship between trimester-specific prenatal maternal serum PFAS levels and paired placental and cord plasma levels at term. Data came from the Central Arkansas Glowing prospective cohort (n=151, 2010-2014). Four well-detected PFAS were measured using liquid chromatography-tandem mass spectrometry. Regression, elastic net, and parametric g-formula models tested the association between maternal levels in each trimester and placental or cord PFAS levels. In g-formula models, trimester one (T1) or trimester two (T2) measures consistently had the largest effect sizes associated with placental levels (p<0.001-0.05). Similarly, T1 (PFHxS, PFNA, PFOS, PFOA), T2 (PFNA, PFOS, PFOA), and placental PFOA were associated with cord plasma levels (p<0.05-p<0.001). Results were robust to time-varying adjustment for estimated glomerular filtration rate, serum albumin, or maternal weight. Predictive models improved with additional timepoint measures. Our findings suggest PFOA may transfer more efficiently from the placenta to cord plasma and early-to-mid gestation maternal serum PFAS measures may serve as the most robust sentinels of fetoplacental exposure burden, suggesting early exposure prevention should be prioritized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.